Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor alpha Monoclonal Antibody Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023728%3A_____%2F18%3AN0000050" target="_blank" >RIV/00023728:_____/18:N0000050 - isvavai.cz</a>
Result on the web
<a href="https://doi.org/10.1002/art.40420|" target="_blank" >https://doi.org/10.1002/art.40420|</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1002/art.40420" target="_blank" >10.1002/art.40420</a>
Alternative languages
Result language
angličtina
Original language name
Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor alpha Monoclonal Antibody Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis
Original language description
Mavrilimumab, a human monoclonal antibody, targets granulocyte-macrophage colony-stimulating factor receptor . We undertook to determine the long-term safety and efficacy of mavrilimumab in rheumatoid arthritis patients in 2 phase IIb studies (1071 and 1107) and in 1 open-label extension study (ClinicalTrials.gov identifier: NCT01712399. In study 1071, patients with an inadequate response to disease-modifying antirheumatic drugs (DMARDs) received mavrilimumab (30, 100, or 150 mg) or placebo every other week plus methotrexate. In study 1107, patients with an inadequate response to anti-tumor necrosis factor agents and/or DMARDs received 100 mg mavrilimumab every other week or 50 mg golimumab every 4 weeks plus methotrexate. Patients entering the open-label extension study received 100 mg mavrilimumab every other week plus methotrexate. Long-term safety and efficacy of mavrilimumab were assessed
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30226 - Rheumatology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
ARTHRITIS & RHEUMATOLOGY
ISSN
2326-5191
e-ISSN
2326-5205
Volume of the periodical
70
Issue of the periodical within the volume
5
Country of publishing house
US - UNITED STATES
Number of pages
11
Pages from-to
679-689
UT code for WoS article
000430912600007
EID of the result in the Scopus database
2-s2.0-85044627852